Clinical Trial Search

Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period — 0.44; 9.81 percent change — p=<0.001

Primary: Content Completion Rate Assessed as Number of Participants Who Completed at Least 6 of the 12 Weeks of the Intervention — 40 Participants

Primary: BreastQ Quality of Life and Satisfaction Questionnaire — 65.32; 67.07 score on a scale — p=0.05

Primary: Percentage of Patients With a Confirmed Tumor Response, Defined as Complete Response or Partial Response Estimated Using Response Evaluation Criteria in Solid Tumors 1.1…

Primary: Number and Types of Tools Required to Retract the Colon or Peri-colorectal Tissues — 0 Cumulative number of additional tools

Primary: Changes in Peri-implant Marginal Bone Level Between Baseline (Implant Placement) and 1 Year Follow up — 0.80; 0.32 millimeters — p=0.009

Primary: Number of Patients With Schirmer I Test (Without Anesthesia) >10mm/5min in the Eligible Eye at Week 4 — 19; 4 Participants — p=0.002

Primary: Incidence Rate of Adverse Events in Patients With COPD Treated With Tio+Olo: Potentially Recurrent Events — 10.63; 0.55; 0.84; 19.71 Events per 100 person-years

Primary: Proportion of Participants With Improvement in Periorbital Wrinkles From Baseline — 10; 2; 8; 2 Participants

Primary: Count of Participants With Adverse Events — 0; 1; 3; 1 Participants

Primary: Progression Free Survival — 77.1 percentage of participants

Primary: Measure Change in Isometric Peak Torque Quadriceps Strength — 2.18; 2.06; 1.96; 1.95 Nm/Kg

Primary: Maximal Knee Extensor Power — 4.20; 4.74 W/kg — p=0.0153

Primary: Change in Glycated Haemoglobin (HbA1c) — -1.57; -1.36 Percentage of HbA1c — p=<0.0001

Primary: Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 — -60.6963 millimeters of mercury (mmHg)